GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor June 14, 2019 - NASDAQ Companies 0 » View More News for June 14, 2019